2型糖尿病新靶点口服药专利分析

Patent analysis of new target oral drugs for type 2 diabetes mellitus

目的 分析2型糖尿病新靶点口服药专利概况,为国内新型糖尿病治疗药物的研发方向和专利布局等提供参考。方法以HimmPat数据库中全球专利数据为基础,从专利申请量及授权量、发展趋势、地域分布、主要申请人等多个角度,对葡萄糖激酶激活剂(GKA)、蛋白酪氨酸磷酸酶1B抑制剂(PTP-1B-IN)、11β-羟基类固醇脱氢酶1抑制剂(11β-HSD1-IN)3类2型糖尿病新靶点口服药相关专利进行统计分析。结果与结论 共检索得到GKA类专利1 649件,PTP-1B-IN类专利709件,11β-HSD1-IN类专利592件。全球主要申请主体为各大药企,其掌握了药物化合物的核心专利;其中GKA类药物的研究更成熟,专利申请量更大,企业布局更全面。国内企业、高校和科研院所在PTP-1B-IN领域具有一定的研究优势。国内企业和研究机构可以发挥传统中药资源优势,提升研究实力,可考虑从核心技术挖掘、工艺路线探索、专利布局、产学研合作、构建专利池等方面提高技术竞争力。

OBJECTIVE To analyze the patents of new target oral drugs for type 2 diabetes mellitus(T2DM),and to provide references for the research and development direction and patent layout of new domestic diabetes drugs.METHODS Based on global patent data in the HimmPat database,from multiple perspectives such as the number of patent applications and authorization,development trend,regional distribution and main applicants,statistics and analysis were performed for the patents related to 3 types of new target oral drugs for T2DM,such as glucokinase activator(GKA),protein tyrosine phosphatase 1B inhibitor(PTP-1B-IN),and 11β-hydroxysteroid dehydrogenase 1 inhibitor(11β-HSD1-IN).RESULTS&CONCLUSIONS A total of 1649 patents of GKA,709 patents of PTP-1B-IN,592 patents of 11β-HSD1-IN were obtained,the main applicants were well-known pharmaceutical companies,which possessed the core patents of pharmaceutical compounds.The research on GKA drugs was more mature,with a larger number of patent applications and a more comprehensive enterprise layout.Domestic enterprises,universities and research institutions had advantages in the field of PTP-1B-IN.Domestic enterprises and research institutions can leverage the advantages of traditional Chinese medicine and resources to enhance their research capabilities and improve technological competitiveness through core technology exploration,the exploration of process route,patent layout,industry-university-research cooperation and the establishment of patent pool.